RANI vs. CHMA, PASG, APEN, GRCL, ABVX, SPRY, IMNM, IRON, CNTA, and CVAC
Should you be buying Rani Therapeutics stock or one of its competitors? The main competitors of Rani Therapeutics include Chiasma (CHMA), Passage Bio (PASG), Apollo Endosurgery (APEN), Gracell Biotechnologies (GRCL), ABIVAX Société Anonyme (ABVX), ARS Pharmaceuticals (SPRY), Immunome (IMNM), Disc Medicine (IRON), Centessa Pharmaceuticals (CNTA), and CureVac (CVAC). These companies are all part of the "medical" sector.
Chiasma (NASDAQ:CHMA) and Rani Therapeutics (NASDAQ:RANI) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, dividends, profitability, institutional ownership, risk, analyst recommendations, community ranking and media sentiment.
Rani Therapeutics has a consensus target price of $12.20, indicating a potential upside of 170.51%. Given Chiasma's higher probable upside, analysts clearly believe Rani Therapeutics is more favorable than Chiasma.
Chiasma received 230 more outperform votes than Rani Therapeutics when rated by MarketBeat users. However, 76.67% of users gave Rani Therapeutics an outperform vote while only 50.91% of users gave Chiasma an outperform vote.
Chiasma's return on equity of -107.61% beat Rani Therapeutics' return on equity.
Rani Therapeutics has higher revenue and earnings than Chiasma. Rani Therapeutics is trading at a lower price-to-earnings ratio than Chiasma, indicating that it is currently the more affordable of the two stocks.
61.7% of Chiasma shares are owned by institutional investors. Comparatively, 30.2% of Rani Therapeutics shares are owned by institutional investors. 8.3% of Chiasma shares are owned by company insiders. Comparatively, 53.3% of Rani Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
In the previous week, Rani Therapeutics had 2 more articles in the media than Chiasma. MarketBeat recorded 2 mentions for Rani Therapeutics and 0 mentions for Chiasma. Chiasma's average media sentiment score of 1.25 beat Rani Therapeutics' score of 0.46 indicating that Rani Therapeutics is being referred to more favorably in the news media.
Chiasma has a beta of 1.28, meaning that its stock price is 28% more volatile than the S&P 500. Comparatively, Rani Therapeutics has a beta of 0.33, meaning that its stock price is 67% less volatile than the S&P 500.
Summary
Rani Therapeutics beats Chiasma on 11 of the 16 factors compared between the two stocks.
Get Rani Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for RANI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RANI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Rani Therapeutics Competitors List
Related Companies and Tools
